8-K: BD Reorganizes Segments, Divests Life Sciences Unit

Becton, Dickinson and Company has reorganized its business into five new segments and announced the future divestiture of its Life Sciences segment.

Summary

• Becton, Dickinson and Company (BD) reorganized its organizational units into five worldwide business segments effective October 1, 2025: Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences.
• The segment reorganization did not affect the principal product lines of any organizational unit.
• BD entered a definitive agreement on July 13, 2025, to combine its Biosciences and Diagnostic Solutions business (part of Life Sciences) with Waters Corporation.
• Subsequent to this separation and combination, the Life Sciences segment will be eliminated from BD's segment reporting, resulting in four reportable segments.
• Recast historical segment revenues for fiscal year 2025 and corresponding prior year periods were provided to assist investors in understanding the new segment structure.
• Total revenues for the twelve months ended September 30, 2025, were $21,840 million, an 8.2% increase (8.1% currency-neutral) from $20,178 million in the prior year.
• Adjusted total revenues, excluding prior-year government legislative and legal matters, grew 7.9% (7.7% currency-neutral) to $21,840 million for the twelve months ended September 30, 2025.
• Total "New BD" adjusted revenue (excluding Life Sciences) increased 9.8% (9.7% currency-neutral) to $18,544 million for the twelve months ended September 30, 2025.
• Organic revenue, excluding legal matters and inorganic adjustments, grew 3.1% (2.9% currency-neutral) to $20,863 million for the twelve months ended September 30, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive strategic move, as the reorganization and divestiture of a declining segment (Life Sciences) are expected to streamline operations and focus on higher-growth areas, as evidenced by the strong 'New BD' revenue growth.

Positives

• Total revenues for the twelve months ended September 30, 2025, increased by 8.2% to $21,840 million, demonstrating strong overall growth.
• The Connected Care segment showed significant growth, with total revenues increasing by 35.2% (34.9% currency-neutral) to $4,556 million for the twelve months ended September 30, 2025, largely driven by the Advanced Patient Monitoring acquisition.
• Total "New BD" adjusted revenue (excluding the divested Life Sciences segment) grew by 9.8% (9.7% currency-neutral) to $18,544 million for the twelve months ended September 30, 2025, indicating robust performance in the core remaining businesses.
• The Interventional segment reported solid growth of 4.8% (4.6% currency-neutral) to $5,217 million for the twelve months ended September 30, 2025.
• Medical Essentials segment revenues increased by 2.9% (3.1% currency-neutral) to $6,446 million for the twelve months ended September 30, 2025.
• BioPharma Systems segment revenues grew by 2.2% (1.6% currency-neutral) to $2,324 million for the twelve months ended September 30, 2025.

Negatives

• The Life Sciences segment experienced a decline in total revenues by 1.8% (2.2% currency-neutral) to $3,296 million for the twelve months ended September 30, 2025.
• Within Life Sciences, Biosciences revenue decreased by 3.6% (4.0% currency-neutral) and Diagnostic Solutions revenue decreased by 0.4% (0.7% currency-neutral) for the twelve months ended September 30, 2025.
• The company recognized accruals relating to the Italian government medical device pay back legislation and another legal matter, totaling $67 million in fiscal year 2024, which negatively impacted reported revenues for that period.

Risks

• Accruals relating to the Italian government medical device pay back legislation represent a past financial liability that could indicate ongoing regulatory complexities in certain markets.
• Another unspecified legal matter also resulted in accruals, indicating potential past or ongoing legal exposures.
• The divestiture of the Life Sciences segment, while strategic, could introduce integration risks with Waters Corporation or impact BD's overall market diversification and future growth profile if the remaining segments do not perform as expected.

Future Outlook

The company anticipates that its Life Sciences segment will be eliminated from segment reporting subsequent to the separation and combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, resulting in a future structure of four reportable segments.

Management Comments

• BD management believes that the use of non-GAAP measures, which adjust for items considered outside of underlying operational results or affecting period-to-period comparability, helps investors gain a better understanding of performance year-over-year, analyze underlying business trends, and understand future prospects.
• Management uses these non-GAAP financial measures to measure and forecast the company's performance, especially when comparing results to prior periods or forecasts.
• Presenting such measures provides investors with greater transparency to the information used by BD management for its operational decision-making and for comparison to other companies within the medical technology industry.

Industry Context

StockSavvy.ai notes that the reorganization of Becton, Dickinson and Company's segments and the divestiture of its Life Sciences business align with a broader industry trend among diversified medical technology companies to streamline portfolios, focus on core growth areas, and enhance operational efficiency. This strategic move, particularly the combination of Biosciences and Diagnostic Solutions with Waters Corporation, suggests a push towards specialization and potentially unlocking value from non-core assets, a common strategy to optimize shareholder returns in a competitive healthcare landscape.

Legal Proceedings

• Accruals relating to the Italian government medical device pay back legislation.
• Accruals relating to another unspecified legal matter.

Stakeholder Impact

• Shareholders: Potential for enhanced shareholder value through a more focused business portfolio and improved growth rates in core segments. The divestiture of a declining segment could be viewed positively.
• Employees: Employees within the Biosciences and Diagnostic Solutions businesses will be impacted by the combination with Waters Corporation. Employees in the remaining segments will operate under a new organizational structure.
• Customers: Customers of the Biosciences and Diagnostic Solutions businesses will transition to Waters Corporation. Customers of the remaining BD segments will continue to be served by the reorganized structure.
• Competitors: The divestiture and reorganization could alter the competitive landscape in both the divested and remaining segments, potentially leading to new strategic alignments or intensified competition.

Next Steps

• Completion of the separation and combination of the Biosciences and Diagnostic Solutions business with Waters Corporation, after which the Life Sciences segment will be eliminated from BD's segment reporting.

Key Dates

Recommendation

The strategic reorganization and divestiture of the underperforming Life Sciences segment, coupled with strong growth in the remaining "New BD" core businesses (especially Connected Care), suggest a more focused and potentially higher-growth company moving forward. The recast financials provide transparency into this improved operational profile, making the stock an attractive "buy" for long-term investors seeking exposure to a streamlined medical technology leader.

Keywords

Becton Dickinson, BD, Segment Reorganization, Divestiture, Life Sciences, Medical Technology, Healthcare, Financial Reporting, Revenue, Non-GAAP, Waters Corporation, Advanced Patient Monitoring